ÂÜÀòÂÒÂ×

Ms. Wendy Johnson has over 30 years’ experience in drug development, venture capital, licensing, strategy, and corporate development in both private and public companies. Ms. Johnson currently serves as Chief Development Officer of Reneo Pharmaceuticals, Inc., and serves on the Board of Directors of MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR and Exagen Inc. (XGN (NasdaqGM).

Ms. Johnson previously served on the Board of Directors of AmpliPhi Biosciences (now Armata Pharmaceuticals (ARMP (NYSE American), the Clearity Foundation, and University of California Moores Cancer Center. Ms. Johnson has also served as the President & CEO of Aires Pharmaceuticals (acquired by Mast Therapeutics). Ms. Johnson served as Senior Vice President, Corporate Development, at Salmedix Inc. (acquired by Cephalon/Teva). Ms. Johnson has additional experience with medical devices, diagnostics, drug discovery and development, and regulatory affairs. In the past Ms. Johnson served as Assistant Director with the Center for Devices and Radiological Health at the U.S. Food and Drug Administration.

Ms. Johnson received an M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School and a B.S. in microbiology from the University of Maryland.